41 results
6-K
EX-10.3
SPRC
SciSparc Ltd
4 Apr 23
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
7:07am
and the Consultant, and the Consultant is not entitled to any social or other benefits resulting from employer-employee relationship. Notwithstanding … payments regarding the Services, social security, unemployment or disability insurance or similar terms in connection with compensation received
6-K
EX-99.3
SPRC
SciSparc Ltd
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
, causing problems in social interaction and communication. The term “spectrum” in autism spectrum disorder refers to the wide range of symptoms
6-K
EX-99.1
SPRC
SciSparc Ltd
24 Jun 22
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:52am
that impacts how a person perceives and socializes with others, causing problems in social interaction and communication. The term “spectrum” in autism
6-K
EX-99.1
SPRC
SciSparc Ltd
11 Aug 22
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:42am
dose.
ASD is a condition related to brain development that impacts how a person perceives and socializes with others, causing problems in social
6-K
EX-99.1
SPRC
SciSparc Ltd
7 Jul 21
Current Report of Private Issuer
4:00pm
and judgment. Neuropsychiatric symptoms such as apathy, social withdrawal, disinhibition, agitation, psychosis, insomnia, poor appetite and wandering are also
6-K
EX-99.1
4ltgpdq68z
29 Jan 24
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
4:00pm
6-K
EX-99.1
t3pchpb24j2lu 0bpc7
17 Feb 21
Report of Foreign Private Issuer
8:35am
6-K
EX-99.2
sgcvvgle3a05n0k2ldwh
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
EX-99.1
kn3rilf1
8 Nov 22
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
7:33am
6-K
EX-99.1
aiwi6v0 ypvcb
6 Jan 22
SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer’s Disease
9:09am
6-K
EX-99.1
cswx6re3sq0mw1l617i
17 Jul 23
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
8:00am
6-K
EX-99.1
p6t60ma
18 Jan 22
SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110
4:27pm
6-K
EX-99.1
5nth4o5pd hglx9e92
2 May 23
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
7:28am
6-K
EX-99.1
h54gyajveho
2 Jun 23
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
9:04am
6-K
EX-99.1
9p0erzeg6j mnn5v89eb
25 Sep 20
Special General Meeting of Shareholders
8:12am
F-1
EX-10.7
s8qer h2gt
27 Feb 24
Registration statement (foreign)
4:15pm
6-K
EX-99.1
ehxvcolv8f azbwpmitr
22 Feb 22
Report of Foreign Private Issuer
9:05am
6-K
EX-99.1
7gck mmn6a
18 Oct 23
Report of Foreign Private Issuer
6:54am
6-K
EX-99.3
uryngvy vp206qzqu
30 Sep 22
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
7:27am